Indaptus Therapeutics (INDP) - צמיחת רווחים בשנה הנוכחית

Indaptus Therapeutics (INDP) is scaling its immune activation platforms to combat cancer, aiming to attract major partners. The annual variable EPS reflects the earnings per share trend, where the latest parameter stands at 0.00. While a team of top-tier scientists is developing bacterial therapies, the company faces intense pressure from industry behemoths and competing immunotherapy technologies.

This metric measures the percentage change in earnings per share compared to the same period last year, reflecting the efficiency of capital generation. Professional investors utilize year-over-year EPS dynamics to assess an issuer's financial resilience to external shocks and market volatility. For Indaptus Therapeutics (INDP), this metric is secondary, as the development of cancer immunotherapy depends on scientific breakthroughs rather than economic cycles.